A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
386
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

GlaxoSmithKline